PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Svoronos Dawn | Director | Jun 09 | Sale | 27.20 | 738 | 20,074 | 29,017 | Jun 10 04:06 PM | Peltz Stuart Walter | CHIEF EXECUTIVE OFFICER | Jun 07 | Sale | 26.83 | 407 | 10,919 | 38,239 | Jun 09 04:03 PM | Klein Matthew B. | CHIEF OPERATING OFFICER | Apr 19 | Sale | 42.52 | 897 | 38,136 | 56,564 | Apr 21 04:03 PM | Pauwels Eric | CHIEF BUSINESS OFFICER | Apr 19 | Sale | 42.52 | 822 | 34,947 | 49,772 | Apr 21 04:02 PM | Peltz Stuart Walter | CHIEF EXECUTIVE OFFICER | Apr 14 | Sale | 45.28 | 82 | 3,713 | 38,646 | Apr 15 04:04 PM | Boulding Mark Elliott | EXEC. VP AND CLO | Apr 13 | Option Exercise | 11.23 | 2,276 | 25,559 | 63,386 | Apr 15 04:02 PM | Boulding Mark Elliott | EXEC. VP AND CLO | Apr 13 | Sale | 45.17 | 2,276 | 102,811 | 61,110 | Apr 15 04:02 PM | Boulding Mark Elliott | EXEC. VP AND CLO | Apr 05 | Option Exercise | 11.23 | 5 | 56 | 61,115 | Apr 07 04:03 PM | Boulding Mark Elliott | EXEC. VP AND CLO | Apr 05 | Sale | 45.00 | 5 | 225 | 61,110 | Apr 07 04:03 PM | Hill Emily Luisa | CHIEF FINANCIAL OFFICER | Mar 31 | Sale | 37.78 | 7,910 | 298,824 | 29,259 | Apr 01 04:20 PM | Boulding Mark Elliott | Exec. VP and CLO | Feb 10 | Option Exercise | 17.15 | 17,935 | 307,537 | 76,763 | Feb 11 04:11 PM | Boulding Mark Elliott | Exec. VP and CLO | Feb 10 | Sale | 45.03 | 17,935 | 807,559 | 61,110 | Feb 11 04:11 PM | Utter Christine Marie | SVP, Finance & CAO | Feb 02 | Sale | 40.38 | 707 | 28,549 | 25,405 | Feb 03 04:59 PM | Boulding Mark Elliott | Exec. VP and CLO | Feb 01 | Sale | 40.00 | 779 | 31,162 | 61,110 | Feb 03 04:57 PM | Hill Emily Luisa | Chief Financial Officer | Feb 01 | Sale | 40.00 | 553 | 22,121 | 37,169 | Feb 03 04:58 PM | Pauwels Eric | Chief Business Officer | Feb 01 | Sale | 40.00 | 367 | 14,681 | 50,594 | Feb 03 04:58 PM | Peltz Stuart Walter | Chief Executive Officer | Feb 01 | Sale | 40.00 | 282 | 11,281 | 38,728 | Feb 03 04:58 PM | Peltz Stuart Walter | Chief Executive Officer | Feb 01 | Sale | 40.00 | 1,961 | 78,444 | 120,485 | Feb 03 04:58 PM | Utter Christine Marie | SVP, Finance & CAO | Feb 01 | Sale | 40.00 | 313 | 12,521 | 26,112 | Feb 03 04:59 PM | Almstead Neil Gregory | Chief Technical Ops Officer | Feb 01 | Sale | 40.00 | 27 | 1,080 | 2,420 | Feb 03 04:57 PM | Almstead Neil Gregory | Chief Technical Ops Officer | Feb 01 | Sale | 40.00 | 605 | 24,201 | 48,853 | Feb 03 04:57 PM | Hill Emily Luisa | Chief Financial Officer | Jan 25 | Sale | 39.31 | 211 | 8,295 | 37,722 | Jan 27 04:01 PM | Pauwels Eric | Chief Business Officer | Jan 25 | Sale | 39.31 | 359 | 14,114 | 50,961 | Jan 27 04:02 PM | Peltz Stuart Walter | Chief Executive Officer | Jan 25 | Sale | 39.31 | 330 | 12,974 | 39,010 | Jan 27 04:02 PM | Almstead Neil Gregory | Chief Technical Ops Officer | Jan 25 | Sale | 39.31 | 43 | 1,691 | 2,447 | Jan 27 04:01 PM | Utter Christine Marie | SVP, Finance & CAO | Jan 18 | Option Exercise | 18.01 | 10,000 | 180,100 | 36,425 | Jan 20 04:50 PM | Utter Christine Marie | SVP, Finance & CAO | Jan 18 | Sale | 43.94 | 11,428 | 502,118 | 26,425 | Jan 20 04:50 PM | Almstead Neil Gregory | Chief Technical Ops Officer | Jan 07 | Sale | 38.52 | 45 | 1,734 | 1,710 | Jan 11 04:20 PM | Almstead Neil Gregory | Chief Technical Ops Officer | Jan 07 | Sale | 38.52 | 756 | 29,125 | 35,058 | Jan 11 04:20 PM | Utter Christine Marie | SVP, Finance & CAO | Jan 07 | Sale | 38.52 | 747 | 28,778 | 16,253 | Jan 11 04:21 PM | Boulding Mark Elliott | Exec. VP and CLO | Jan 07 | Sale | 38.52 | 885 | 34,095 | 47,489 | Jan 11 04:19 PM | Klein Matthew B. | Chief Operating Officer | Jan 07 | Sale | 38.52 | 775 | 29,857 | 16,461 | Jan 11 04:18 PM | Hill Emily Luisa | Chief Financial Officer | Jan 07 | Sale | 38.52 | 800 | 30,820 | 22,333 | Jan 11 04:18 PM | Pauwels Eric | Chief Business Officer | Jan 07 | Sale | 38.52 | 866 | 33,363 | 34,520 | Jan 11 04:17 PM | Peltz Stuart Walter | Chief Executive Officer | Jan 07 | Sale | 38.52 | 294 | 11,326 | 22,540 | Jan 11 04:16 PM | Peltz Stuart Walter | Chief Executive Officer | Jan 07 | Sale | 38.52 | 1,869 | 72,003 | 78,446 | Jan 11 04:16 PM | Svoronos Dawn | Director | Jan 07 | Sale | 38.52 | 510 | 19,648 | 26,555 | Jan 11 04:14 PM | Hill Emily Luisa | Chief Financial Officer | Jan 04 | Sale | 41.16 | 173 | 7,121 | 23,133 | Jan 06 04:10 PM | Almstead Neil Gregory | Chief Technical Ops Officer | Jan 04 | Sale | 41.16 | 64 | 2,634 | 1,755 | Jan 06 04:10 PM | Peltz Stuart Walter | Chief Executive Officer | Jan 04 | Sale | 41.16 | 378 | 15,559 | 22,834 | Jan 06 04:08 PM | Pauwels Eric | Chief Business Officer | Jan 04 | Sale | 41.16 | 806 | 33,177 | 35,386 | Jan 06 04:09 PM | Boulding Mark Elliott | Exec. VP and CLO | Sep 02 | Option Exercise | 18.01 | 3,363 | 60,568 | 51,737 | Sep 03 04:06 PM | Boulding Mark Elliott | Exec. VP and CLO | Sep 02 | Sale | 45.01 | 3,363 | 151,375 | 48,374 | Sep 03 04:06 PM | Okey Stephanie | Director | Aug 13 | Sale | 40.06 | 1,650 | 66,094 | 963 | Aug 17 04:04 PM | Boulding Mark Elliott | Exec. VP and CLO | Jul 09 | Option Exercise | 18.01 | 1,429 | 25,736 | 48,922 | Jul 12 04:26 PM | Boulding Mark Elliott | Exec. VP and CLO | Jul 09 | Sale | 45.00 | 1,429 | 64,306 | 48,374 | Jul 12 04:26 PM | Boulding Mark Elliott | Exec. VP and CLO | Jul 08 | Option Exercise | 16.27 | 7,805 | 127,008 | 50,174 | Jul 12 04:26 PM | Boulding Mark Elliott | Exec. VP and CLO | Jul 08 | Sale | 45.22 | 7,805 | 352,968 | 48,374 | Jul 12 04:26 PM |
|